Table 3. The pharmacological effects of drugs.
| IDs | Rapamycin | Wortmannin | PDTC | 1400W |
|---|---|---|---|---|
| REACTOME.PATH | ||||
| Homo sapiens: Activation of NF-κB in B Cells | 4 (1.12e-05) | 0 (1) | 3 (2.43e-05) | 3 (8.73e-06) |
| Homo sapiens: Cross-presentation of soluble exogenous antigens (endosomes) | 3 (0.000144) | 0 (1) | 3 (9.27e-06) | 3 (3.32e-06) |
| Homo sapiens: Regulation of activated PAK-2p34 by proteasome mediated degradation | 3 (0.000144) | 0 (1) | 3 (9.27e-06) | 3 (3.32e-06) |
| Homo sapiens: Regulation of ornithine decarboxylase (ODC) | 3 (0.000153) | 0 (1) | 3 (9.87e-06) | 3 (3.53e-06) |
| Homo sapiens: Ubiquitin-dependent degradation of Cyclin D | 3 (0.000153) | 0 (1) | 3 (9.87e-06) | 3 (3.53e-06) |
| Homo sapiens: Ubiquitin-dependent degradation of Cyclin D1 | 3 (0.000153) | 0 (1) | 3 (9.87e-06) | 3 (3.53e-06) |
| Homo sapiens: CDK-mediated phosphorylation and removal of Cdc6 | 3 (0.000153) | 0 (1) | 3 (9.87e-06) | 3 (3.53e-06) |
| Homo sapiens: Vpu mediated degradation of CD4 | 3 (0.000162) | 0 (1) | 3 (1.05e-05) | 3 (3.76e-06) |
| Human immunodeficiency virus 1: Vpu mediated degradation of CD4 | 3 (0.000183) | 0 (1) | 3 (1.18e-05) | 3 (4.23e-06) |
| Homo sapiens: p53-Independent G1/S DNA damage checkpoint | 3 (0.000183) | 0 (1) | 3 (1.18e-05) | 3 (4.23e-06) |
| Homo sapiens: p53-Independent DNA Damage Response | 1 (p > 0.05) | 2 (0.00166) | 0 (1) | 0 (1) |
| Homo sapiens: Translocation of GLUT4 to the Plasma Membrane | 1 (0.0107) | 1 (0.00439) | 0 (1) | 0 (1) |
| Homo sapiens: Glyoxylate metabolism | 1 (0.0128) | 1 (0.00527) | 0 (1) | 0 (1) |
| Danio rerio: Interleukin receptor SHC signaling | 1 (0.017) | 1 (0.00702) | 0 (1) | 0 (1) |
| Drosophila melanogaster: Purine catabolism | 0 (1) | 1 (0.00877) | 0 (1) | 0 (1) |
| Homo sapiens: GP1b-IX-V activation signalling | 1 (0.0212) | 1 (0.00877) | 0 (1) | 0 (1) |
| Danio rerio: Interleukin-6 signaling | 1 (0.0233) | 1 (0.00964) | 0 (1) | 0 (1) |
| Drosophila melanogaster: Pyrimidine catabolism | 1 (p > 0.05) | 2 (0.0129) | 0 (1) | 0 (1) |
| Homo sapiens: Membrane Trafficking | 1 (0.0317) | 1 (0.0131) | 0 (1) | 0 (1) |
| Danio rerio: Prolactin receptor signaling | 0 (1) | 1 (0.014) | 1 (0.0147) | 0 (1) |
| Mus musculus: N-Glycan antennae elongation | 4 (0.000214) | 0 (1) | 4 (4.89e-06) | 3 (8.37e-05) |
| Homo sapiens: Mitotic G1-G1/S phases | 3 (0.000183) | 0 (1) | 3 (1.18e-05) | 3 (4.23e-06) |
| DOLite | ||||
| Skin disease | 2 (0.00295) | 1 (0.025) | 0 (1) | 0 (1) |
| Skin tumor | 1 (0.0172) | 1 (0.00518) | 0 (1) | 0 (1) |
| Histiocytosis | 1 (0.022) | 0 (1) | 0 (1) | 0 (1) |
| Conduct disorder | 1 (0.0244) | 0 (1) | 0 (1) | 0 (1) |
| Dermatitis | 2 (0.034) | 0 (1) | 0 (1) | 0 (1) |
| Infiltrating cancer | 1 (0.0341) | 0 (1) | 0 (1) | 0 (1) |
| Pervasive development disorder | 1 (0.0365) | 0 (1) | 0 (1) | 0 (1) |
| Sarcoma | 1 (0.0412) | 1 (0.0125) | 0 (1) | 0 (1) |
| Skin cancer | 1 (0.046) | 1 (0.014) | 0 (1) | 0 (1) |
| Testicular dysfunction | 1 (p > 0.05) | 0 (1) | 1 (0.0121) | 0 (1) |
| Spondylarthropathies | 0 (1) | 0 (1) | 0 (1) | 1 (0.00222) |
| Arthritis | 0 (1) | 0 (1) | 0 (1) | 1 (0.016) |
| GO.BP | ||||
| Regulation of cellular amino acid metabolic process | 3 (0.000158) | 0 (1) | 3 (3.19e-06) | 3 (2e-06) |
| DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | 3 (0.000232) | 0 (1) | 3 (4.72e-06) | 3 (2.96e-06) |
| Signal transduction involved in mitotic cell cycle checkpoint | 3 (0.000232) | 0 (1) | 3 (4.72e-06) | 3 (2.96e-06) |
| Signal transduction involved in mitotic cell cycle G1/S transition DNA damage checkpoint | 3 (0.000232) | 0 (1) | 3 (4.72e-06) | 3 (2.96e-06) |
| Signal transduction involved in mitotic cell cycle G1/S checkpoint | 3 (0.000232) | 0 (1) | 3 (4.72e-06) | 3 (2.96e-06) |
| Negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle | 3 (0.000242) | 0 (1) | 3 (4.94e-06) | 3 (3.1e-06) |
| Signal transduction involved in DNA integrity checkpoint | 3 (0.000242) | 0 (1) | 3 (4.94e-06) | 3 (3.1e-06) |
| Signal transduction involved in G1/S transition checkpoint | 3 (0.000242) | 0 (1) | 3 (4.94e-06) | 3 (3.1e-06) |
| Signal transduction involved in DNA damage checkpoint | 3 (0.000242) | 0 (1) | 3 (4.94e-06) | 3 (3.1e-06) |
| Regulation of cellular ketone metabolic process | 4 (0.000249) | 0 (1) | 3 (8.22e-05) | 3 (5.18e-05) |
| Establishment of protein localization to organelle | 2 (p > 0.05) | 3 (2.87e-05) | 0 (1) | 0 (1) |
| Cellular protein localization | 3 (p > 0.05) | 4 (8.85e-05) | 0 (1) | 0 (1) |
| Cellular macromolecule localization | 3 (p > 0.05) | 4 (9e-05) | 0 (1) | 0 (1) |
| Protein targeting to mitochondrion | 1 (p > 0.05) | 2 (0.000131) | 0 (1) | 0 (1) |
| Establishment of protein localization to mitochondrion | 1 (p > 0.05) | 2 (0.000156) | 0 (1) | 0 (1) |
| Protein localization to mitochondrion | 1 (p > 0.05) | 2 (0.000162) | 0 (1) | 0 (1) |
| Protein targeting | 2 (p > 0.05) | 3 (0.000334) | 0 (1) | 0 (1) |
| Oxalic acid secretion | 1 (0.00183) | 1 (0.000339) | 0 (1) | 0 (1) |
| Protein localization to organelle | 2 (p > 0.05) | 3 (0.000404) | 0 (1) | 0 (1) |
| Protein localization | 3 (p > 0.05) | 4 (0.000642) | 1 (p > 0.05) | 0 (1) |
| Signal transduction involved in cell cycle checkpoint | 3 (0.000253) | 0 (1) | 3 (5.17e-06) | 3 (3.24e-06) |
| Number of genes | 75 | 35 | 26 | 11 |
Legend: «↑» - increasing, «↓» - decreasing, “=” – no effect, “-” - not studied, M - median lifespanl, 90% - age of 90% mortality; LA - locomotor activity; F - fertility; *p <0.05, **p <0.01, Gehan–Breslow–Wilcoxon test and Mantel–Cox test for M and Wang-Allison test for 90%.